What is William Blair’s Estimate for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at William Blair issued their Q1 2025 EPS estimates for Tenax Therapeutics in a report issued on Wednesday, March 26th. William Blair analyst M. Phipps anticipates that the specialty pharmaceutical company will earn ($0.19) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.87) EPS and FY2026 earnings at ($0.94) EPS.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.34.

Other equities analysts also recently issued reports about the company. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a research report on Monday, March 10th. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research report on Friday, March 21st. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Tenax Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Stock Up 0.8 %

NASDAQ TENX opened at $6.18 on Friday. The company has a market cap of $24.50 million, a price-to-earnings ratio of -1.16 and a beta of 2.20. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The business’s fifty day moving average is $6.43 and its 200 day moving average is $5.40.

Hedge Funds Weigh In On Tenax Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP acquired a new stake in shares of Tenax Therapeutics during the fourth quarter worth $84,000. Sphera Funds Management LTD. bought a new stake in Tenax Therapeutics during the third quarter valued at $101,000. Geode Capital Management LLC grew its holdings in Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares during the period. Millennium Management LLC bought a new position in shares of Tenax Therapeutics in the 4th quarter worth about $166,000. Finally, Vestal Point Capital LP acquired a new position in shares of Tenax Therapeutics in the 3rd quarter valued at about $288,000. 1.67% of the stock is currently owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.